Atrion (NASDAQ:ATRI) Stock Rating Lowered by StockNews.com

Atrion (NASDAQ:ATRIGet Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Atrion Price Performance

NASDAQ ATRI opened at $471.99 on Tuesday. The company’s fifty day moving average is $427.41 and its two-hundred day moving average is $375.64. Atrion has a 52-week low of $274.98 and a 52-week high of $602.59. The firm has a market capitalization of $830.70 million, a price-to-earnings ratio of 44.36 and a beta of 0.62.

Atrion (NASDAQ:ATRIGet Free Report) last released its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $47.33 million during the quarter.

Hedge Funds Weigh In On Atrion

Hedge funds have recently made changes to their positions in the business. Copeland Capital Management LLC raised its position in Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 31 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Atrion in the 4th quarter worth approximately $36,000. Harbor Investment Advisory LLC lifted its position in shares of Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 47 shares during the period. EntryPoint Capital LLC acquired a new stake in Atrion in the 1st quarter valued at $91,000. Finally, Tower Research Capital LLC TRC grew its position in Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares during the period. Institutional investors and hedge funds own 66.19% of the company’s stock.

Atrion Company Profile

(Get Free Report)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Stories

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.